Case Report
Copyright ©The Author(s) 2021.
World J Hepatol. Feb 27, 2021; 13(2): 261-269
Published online Feb 27, 2021. doi: 10.4254/wjh.v13.i2.261
Table 1 Review of the literature including patients submitted to preoperative trans-arterial radioembolization for colorectal liver metastases
Ref.
Year
Type of study
Pts included, n
CRLM1, n (%)
Tumor location (n)
Bilobar n (%)
Prior resection, n (%)
Resectability, n (%)
Gray et al[18]2001HAI vs HAI + TARE in unresectable CRLM; RCT7436 (48.6)Colon (29), rectum (7)36/36 (100)01/36 (2.8)
Lim et al[6]2005TARE after failure of FU in unresectable CRLM; prospective3030 (100)NANA01/30 (3.3)
Sharma et al[7]2007TARE + FOLFOX4 in unresectable CRLM; prospective (phase I)2020 (100)Right colon (4), sigmoid (5), rectum (4), other colon sites (7)NA02/20 (10)
Cosimelli et al[19]2010TARE in unresectable CRLM; prospective (phase II)5050 (100)Colon (41), rectum (9)35/50 (70)12/50 (24.0)2/50 (4.0)
Hendlisz et al[8]2010FU vs TARE + FU in unresectable CRLM; RCT4421 (47.7)NANANA1/21 (4.8)
Brown et al[9]2011TARE vs CHT vs no therapy before hepatectomy; case-control84016 (1.9)NANANA16/16 (100)
Whitney et al[10]2011TARE in unresectable liver disease; retrospective 4415 (34)Rectum (15)001/15 (6.7)
Vouche et al[11]2013TARE in unresectable liver disease; retrospective838 (9.6)NA001 (12.5)
Wang et al[20]2013TARE before liver resection for CRLM; retrospective2424 (100)Sigmoid (1), rectum (1), other colon sites (1), unknown (21)1/3 (33.3)03/24 (12.5)
Henry et al[12]2015TARE before liver resection for metastatic cancer; retrospective94 (44.4)NANA04/4 (100)
Justinger et al[22]2015TARE in marginally resectable CRLM; retrospective1313 (100)Right colon (2), sigmoid (4), rectum (7)9/13 (69.2)7/13 (53.8)211/13 (84.6)
Moir et al[13]2015TARE in unresectable liver disease; retrospective4422 (50)NANANA4/22 (18.2)
Maleux et al[14]2016TARE in unresectable CRLM; NA8871 (80.6)NA58/71 (81.6)10/71 (14.0)1/71 (1.4)
Lewandowski et al[23]2016TARE in unresectable right-sided liver disease; retrospective131 (7.6)NA0NA1/1 (100)
Wright et al[15]2017TARE in unresectable liver disease; retrospective4656 (1.2)NANANA6/6 (100)
van Hazel et al[16]2016FOLFOX6 vs FOLFOX6 + TARE ± Bevacizumab; RCT530267 (50.3)Left colon (141), right colon (72), rectum (45), other colon sites (7), unknown (2)NANA38/267 (14.2)
Pardo et al[21]2017TARE before liver resection or transplantation; retrospective10030 (30)NA44/1007/30 (23.3)230/30 (100)
Wasan et al[17]2017FOLFOX vs FOLFOX + TARE; RCT1103554 (50.2)Colon (421), rectum (116), unknown (17)NANA56/554 (10.1)
Table 2 Review of the literature including patients submitted to preoperative trans-arterial radioembolization for colorectal liver metastases
Ref.
FLR increase %
Time TARE-surgery, median (range), mo
Type of hepatic resection (n)
Post-operative mortality %
Survival, median (range), mo
Disease free, median (range), mo
Recurrence after surgery, n (%)
Gray et al[18]NANANA096NANA
Lim et al[6]NANANANANA22 1/1 (100)
Sharma et al[7]NANALLS + S6 (1), RH + S3 (1)NANANANA
Hendlisz et al[8]NANARH (1)0NA1.51/1 (100)
Brown et al[9]NA6.5 (4-13)NANANANANA
Whitney et al[10]NANART (1)0NA241/1 (100)
Vouche et al[11]NANART (1)0NANANA
Wang et al[20]NANA (4-9)RH (2), LH + S6 (1)0NANANA
Henry et al[12]NA5 (2-8)LLS (1), multiple wedge, HAI pump (1), RT + RFA (1), RT (1)5013 (0-27)6.2 (1.8-10.5)3/4 (75)
Justinger et al[22]32.9 (ALPPS), 27.1 (no ALPPS)2 (1-5)RT (4), RH (5), mesohepatectomy (1), LT (1)7.625 (12-38)1NANA
Moir et al[13]NA4 (2-11)NA015 (11-19)1NANA
Maleux et al[14]NANAS + RFA (1)0NANANA
Lewandowski et al[23]151.6 (1-7)RT (1)04.8NANA
Wright et al[15]NA9 (3-20)RT (2), S (1), RH (3)16.6 25 (NA)NANA
van Hazel et al[16]NANANA0NANANA
Pardo et al[21]NANANA10NANANA
Wasan et al[17]NANANA3.6NANANA